Atrial Flutter Market Report 2026

The atrial flutter market size has grown rapidly in recent years. It will grow from $22.99 billion in 2025 to $26.52 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to increasing prevalence of cardiac arrhythmias, rising aging population, expansion of cardiology specialty clinics, adoption of ecg-based diagnostic tools, availability of pharmacological rhythm control therapies.

The atrial flutter market size is expected to see rapid growth in the next few years. It will grow to $46.47 billion in 2030 at a compound annual growth rate (CAGR) of 15%. The growth in the forecast period can be attributed to increasing demand for minimally invasive cardiac procedures, rising adoption of digital cardiac monitoring, expansion of personalized arrhythmia treatment approaches, growing investments in electrophysiology technologies, increasing focus on stroke prevention strategies. Major trends in the forecast period include increasing adoption of advanced cardiac mapping technologies, rising use of catheter ablation procedures, growing integration of wearable cardiac monitoring devices, expansion of early diagnosis and screening programs, enhanced focus on minimally invasive treatments.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the atrial flutter market in the coming years. Cardiovascular diseases (CVDs) encompass a wide range of conditions affecting the heart and blood vessels. Factors such as aging populations, sedentary lifestyles, unhealthy diets, increasing obesity rates, and stress contribute to the growing incidence of these conditions. As cardiovascular diseases become more common, the number of individuals at risk for atrial flutter rises, increasing the demand for diagnostic and treatment solutions. For example, in September 2024, according to the British Heart Foundation, a UK-based cardiovascular research charity, approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including 4 million men and 3.6 million women. By 2030, this number is projected to increase by 1 million, and by 2040, it could rise by an additional 2 million. Therefore, the increasing prevalence of cardiovascular diseases is fueling the atrial flutter market.

Key companies in the atrial flutter market are focusing on integrating advanced monitoring technologies, such as arrhythmia detection algorithms, to improve diagnostic precision, treatment outcomes, and patient management. Arrhythmia detection algorithms are specialized software tools that analyze data from electrocardiograms (ECGs) or wearable heart monitors to identify irregular heart rhythms and detect abnormal patterns indicative of arrhythmias like atrial flutter. For instance, in May 2024, Vivalink, Inc., a US-based connected health technology company, launched a turnkey ambulatory cardiac monitoring solution for mobile cardiac telemetry (MCT) and Holter monitoring to enhance remote patient care. The solution uses advanced software to continuously analyze data from ECGs and wearable heart monitors, providing real-time detection of irregular rhythms, including atrial flutter. It features a reusable ECG patch with a 14-day rechargeable battery and up to 30 days of data storage, a mobile gateway integrated with a patient app for seamless data transfer, an algorithm capable of detecting over 15 arrhythmias, and a clinician portal for detailed analysis and customizable reporting.

In July 2024, Stereotaxis Inc., a US-based provider of robotic systems for minimally invasive endovascular and cardiac electrophysiology procedures, acquired Access Point Technologies EP (APT) for approximately USD 15.1 million. This acquisition allows Stereotaxis to leverage APT’s electrophysiology catheter design, development, and manufacturing capabilities, strengthening its in-house catheter portfolio and enhancing its integrated robotic-guided cardiac ablation solutions. The acquisition also expands Stereotaxis’ product range and customer reach across electrophysiology laboratories. Access Point Technologies EP Inc. is a US-based provider of diagnostic electrophysiology catheters and related devices for cardiac mapping and ablation procedures, recognized for its high-performance, clinician-informed catheter designs.

Major companies operating in the atrial flutter market are Pfizer Inc., Johnson & Johnson, Siemens AG, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Medtronic PLC, Boehringer Ingelheim GmbH, Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Astellas Pharma Inc., Zoll Medical Corporation, St. Jude Medical Inc., Biotronik SE & Co., iRhythm Technologies Inc., AtriCure Inc., Adagio Medical Inc., Acutus Medical Inc., Abbott Vascular.

North America was the largest region in the atrial flutter market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial flutter market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atrial flutter market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the atrial flutter market by increasing costs of imported electrophysiology catheters, cardiac mapping systems, diagnostic devices, and implantable monitoring equipment. Hospitals and cardiac centers in North America and Europe are most affected due to dependence on imported cardiovascular devices, while Asia-Pacific faces cost pressure on advanced diagnostic adoption. These tariffs are increasing procedural costs and delaying technology upgrades. However, they are also encouraging regional device manufacturing, local supplier development, and investment in cost-efficient cardiac treatment technologies.

The atrial flutter market research report is one of a series of new reports that provides atrial flutter market statistics, including atrial flutter industry global market size, regional shares, competitors with a atrial flutter market share, detailed atrial flutter market segments, market trends and opportunities, and any further data you may need to thrive in the atrial flutter industry. This atrial flutter market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atrial flutter is a type of abnormal heart rhythm in which rapid, irregular electrical signals occur in the atria, the upper chambers of the heart, resulting in a fast and often irregular heartbeat. This condition can lead to symptoms such as palpitations, shortness of breath, and fatigue, and it may increase the risk of stroke and other cardiovascular complications.

The primary types of atrial flutter include typical atrial flutter, atypical atrial flutter, left atrial flutter, reverse typical atrial flutter, and incisional atrial re-entry. Typical atrial flutter is a common arrhythmia in which electrical signals in the right atrium circulate in a defined pattern, producing a rapid yet regular heartbeat. Treatment options for atrial flutter include antiarrhythmic medications, beta-blockers, anticoagulants, cardioversion, catheter ablation, surgery, and others. Diagnostic methods include heart monitoring, blood tests, electrocardiography (ECG), event monitoring, and others. Administration routes for treatments may be oral, intravenous, or others, and services are provided to various end users such as clinics, hospitals, and other healthcare facilities.

The atrial flutter market consists of revenues earned by entities by providing services such as treatment services, diagnostic testing, and consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The atrial flutter market also includes sales of cardioversion devices, catheter ablation equipment, and monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.